Clinical Trial Update: Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients [Phase 1, Phase 2]

View source ↗

Summary

This update reports safety and immunogenicity data from a Phase 1/2 trial of a Melan-A virus-like particle vaccine in patients with advanced melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Melan-A VLP vaccine (Melan-A virus-like particle vaccine)

Snippet

Sponsor: Cytos Biotechnology AG | Conditions: Melanoma | Phase 1, Phase 2 | Status: COMPLETED